DDInter1042 DDInter708
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Ezogabine {u} (Compound) resembles {v} (Compound) Flupirtine
Ezogabine {u} (Compound) binds {v} (Gene) UGT1A1
Ezogabine {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Openers
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ezogabine (Compound) resembles Flupirtine (Compound)
Ezogabine (Compound) binds UGT1A1 (Gene)
Ezogabine (Compound) is included by Potassium Channel Openers (Pharmacologic Class)
Ezogabine (Compound) causes Ill-defined disorder (Side Effect)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezogabine may lead to a major life threatening interaction when taken with Nilotinib
Ezogabine may lead to a major life threatening interaction when taken with Crizotinib